Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Electra Therapeutics, Inc.

News headline image
Electra Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference in London
From Electra Therapeutics, Inc.
Via GlobeNewswire
Tickers ETRA
News headline image
Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering
From Electra Therapeutics, Inc.
Via GlobeNewswire
News headline image
Electra Therapeutics Announces Initiation of a Phase 1 Trial of ELA822, a Novel SIRPγ-Specific Antibody Designed to Treat T Cell-Mediated Immune and Inflammatory Diseases
From Electra Therapeutics, Inc.
Via GlobeNewswire
News headline image
Electra Therapeutics Appoints Chris Clark, CFA, to Chief Financial Officer
From Electra Therapeutics, Inc.
Via GlobeNewswire
News headline image
Electra Therapeutics Presents Positive Clinical Results From Completed Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in an Oral Session at ASH 2024
From Electra Therapeutics, Inc.
Via Business Wire
News headline image
Electra Therapeutics to Present Clinical Results for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in an Oral Session at ASH 2024
From Electra Therapeutics, Inc.
Via Business Wire
News headline image
Electra Therapeutics Receives FDA Fast Track Designation for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
From Electra Therapeutics, Inc.
Via Business Wire
News headline image
Electra Therapeutics Receives FDA Orphan Drug Designation for ELA026 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
From Electra Therapeutics, Inc.
Via Business Wire
News headline image
Electra Therapeutics Presents Late-Breaking Clinical Data at EHA2024 from Ongoing Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
From Electra Therapeutics, Inc.
Via Business Wire
News headline image
Electra Therapeutics to Present ELA026 Clinical Data in Late-Breaking Oral Session at the 2024 European Hematology Association (EHA) Congress
From Electra Therapeutics, Inc.
Via Business Wire
News headline image
Electra Therapeutics presents first clinical data from ongoing Phase 1b study of ELA026 for treatment of secondary hemophagocytic lymphohistiocytosis (sHLH)
From Electra Therapeutics, Inc.
Via Business Wire
News headline image
Electra Therapeutics Appoints Kathy Dong, PharmD, MBA, as President and Chief Executive Officer
From Electra Therapeutics, Inc.
Via Business Wire
News headline image
Electra Therapeutics to Present Clinical Data for ELA026 at the American Society of Hematology (ASH) 2023 Annual Meeting
From Electra Therapeutics, Inc.
Via Business Wire
News headline image
Electra Therapeutics highlights ELA026 Phase 1b study in sHLH and presents preclinical data at ASH Annual Meeting
From Electra Therapeutics, Inc.
Via Business Wire
News headline image
Electra Therapeutics to Highlight ELA026 in Three Presentations at the American Society of Hematology (ASH) 2022 Annual Meeting
From Electra Therapeutics, Inc.
Via Business Wire
News headline image
Electra Therapeutics Announces $84 Million Series B Financing and Unveils Its Novel SIRP‑Targeted Therapies for Immunological Diseases and Cancer
From Electra Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.